|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8487129||PROGENICS PHARMS INC||Heterodimers of glutamic acid|| |
(4 years from now)
|US9861713||PROGENICS PHARMS INC||PSMA-binding agents and uses thereof|| |
(5 years from now)
|US8778305||PROGENICS PHARMS INC||PSMA-binding agents and uses thereof|| |
(7 years from now)
|US10947197||PROGENICS PHARMS INC||Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL|| |
(13 years from now)
Pylarify is owned by Progenics Pharms Inc.
Pylarify contains Piflufolastat F-18.
Pylarify has a total of 4 drug patents out of which 0 drug patents have expired.
Pylarify was authorised for market use on 26 May, 2021.
Pylarify is available in solution;intravenous dosage forms.
Pylarify can be used as method of positron emission tomography (pet) in men with prostate cancer.
Drug patent challenges can be filed against Pylarify from 2025-05-26.
The generics of Pylarify are possible to be released after 09 June, 2037.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||May 26, 2026|
NCE-1 date: 2025-05-26
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic